Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 60.36
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Data is available to registered users only
Buy
Sell